Inhaled Nitric Oxide for Severe ARDS Mortality Reduction

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for severe acute respiratory distress syndrome (ARDS) using inhaled nitric oxide (iNO) have shown limited efficacy in improving survival rates and are not recommended due to lack of significant impact on mortality, despite transient improvements in arterial oxygenation.

Innovation Solution

Administration of a gaseous drug containing nitrogen monoxide (NO) by inhalation to patients with severe ARDS, characterized by a PaO2/FiO2 ratio ≤80 mmHg and elevated carbon dioxide partial pressure (PaCO2) and low blood pH, improving oxygenation and reducing mortality by altering the severity index and blood gas parameters.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Quantity of substance

If inhaled nitric oxide (iNO) is administered to treat severe ARDS, then arterial oxygenation is improved, but mortality rate is not reduced

Engineering Contradiction:

Improvearterial oxygenationVSAvoidmortality rate

Core Design Contradiction:

Quantity of substanceVSReliability

Solution Approach 1:

The patent applies local quality by targeting a specific subpopulation of severe ARDS patients with PaO2/FiO2 ≤80 mmHg who have not responded to conventional ventilation, rather than applying iNO universally. This selective approach identifies patients with specific physiological characteristics (severe hypoxaemia despite appropriate ventilatory management) who are most likely to benefit from iNO therapy, thereby improving mortality outcomes in the targeted group while avoiding unnecessary exposure in others.

Inventive Principle:

Principle #3Local quality

Solution Approach 2:

The patent changes the therapeutic parameter threshold by defining a specific severity cutoff (PaO2/FiO2 ≤80 mmHg) to identify the target subpopulation. This parameter-based selection criterion transforms the treatment approach from universal iNO administration to targeted therapy based on measured physiological parameters, resolving the contradiction by ensuring treatment is applied only to patients whose severity profile predicts benefit.

Inventive Principle:

Principle #35Parameter changes

2Productivity

If inhaled nitric oxide (iNO) is administered to improve oxygenation in severe ARDS, then gas exchange is enhanced, but survival benefit is not achieved

Engineering Contradiction:

Improvegas exchangeVSAvoidsurvival rate

Core Design Contradiction:

ProductivityVSReliability

Solution Approach 1:

The patent applies preliminary action by selecting patients based on pre-established severity criteria (PaO2/FiO2 ≤80 mmHg) before initiating iNO therapy. This preliminary identification and selection process ensures that only patients with the specific physiological profile most likely to respond to iNO are treated, thereby converting the transient oxygenation improvement into actual survival benefit by preventing treatment in non-responsive patients.

Inventive Principle:

Principle #10Preliminary action

Solution Approach 2:

The patent implements feedback by using the PaO2/FiO2 ratio as a selection criterion that reflects the patient's response to conventional ventilation. Patients who maintain severe hypoxaemia (PaO2/FiO2 ≤80 mmHg) despite appropriate ventilatory management provide feedback that they require alternative therapy, triggering the escalation to iNO treatment and thereby linking gas exchange assessment to survival outcome improvement.

Inventive Principle:

Principle #23Feedback

3Ease of operation

If conventional ventilation is used to treat severe ARDS, then mechanical support is provided, but ventilator-induced lung injury occurs

Engineering Contradiction:

Improvemechanical ventilationVSAvoidventilator-induced lung injury

Core Design Contradiction:

Ease of operationVSObject-affected harmful factors

Solution Approach 1:

The patent introduces iNO as an intermediary substance that modifies the interaction between the ventilator and the patient's lungs. By adding this pharmacological mediator to the ventilation system, the patent enables improved gas exchange with potentially lower ventilator settings, thereby reducing the mechanical stress and shear forces that cause ventilator-induced lung injury while maintaining adequate oxygenation in the selected subpopulation.

Inventive Principle:

Principle #24Intermediary (Mediator)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

Significantly improves survival in a subpopulation of adult patients with severe ARDS by enhancing oxygenation and reducing mortality, as demonstrated by a 48.4% response rate within 6 hours of iNO administration, contrasting with previous studies showing no benefit on mortality.

Implementation Method 1

Methodology Applied

Scientific EffectNitric oxide inhalation effect:

Data Source

PatentUS20240374856A1Inhaled no for treating an adult patient with severe ards

Publication Date: 2024.11.14 LAIR LIQUIDE SA POUR LETUDE & LEXPLOITATION DES PROCEDES GEORGES CLAUDE

AI summary

The invention relates to a gaseous drug containing nitric oxide (NO) gas, such as an NO/nitrogen mixture, for use in the treatment of a patient suffering from acute respiratory distress syndrome (ARDS), comprising administration by inhalation of said gaseous drug to said patient. The patient is an adult suffering from severe ARDS characterized by a severity index (PaO2/FiO2) of less than 80 mmHg, a partial pressure of carbon dioxide (PaCO2) of at least 60 mm Hg and a blood pH of less than 7.25. Preferably, the gaseous drug contains from 200 to 2000 ppmv of NO, with the remainder being nitrogen.